静脉输注新型溶瘤腺病毒在体内复制活性与抑瘤的关系  

The Relationship of Replication and Inhibiting Tumor of New Oncolytic Adenovirus by Intravenous Infusion in Vivo

作　　者：周晓曦[1] 李钦璐[1] 黄闪[1] 姜利军[1] 周剑峰[1] 曹阳[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院血液内科,湖北武汉430030

出　　处：《现代生物医学进展》2012年第19期3624-3627,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金青年基金(81001049)

摘　　要：目的:观察新型溶瘤腺病毒M1在体内代谢的时间及对肿瘤生长的抑制作用。方法:建立人胃癌裸鼠原位移植瘤动物模型,在指定时间点处死动物,观察瘤体大小,分离原发瘤及转移瘤进行病毒滴度测定,采用免疫组化及原位杂交来检测病毒的分布和活性复制。结果:在人胃癌裸鼠原位模型上,M1经静脉输注后不仅分布于胃原发瘤,而且存在于转移灶,但用M1静脉内给药可以减缓肿瘤生长速度。结论:静脉内输注溶瘤腺病毒可以选择性的作用于肿瘤及转移灶,并发挥溶瘤和靶向灭活plk1的双重效应。Objective： To investigate the metabolism time of new oncolytic adenovirus M1 distributing in body and effects of inhibiting tumor. Methods： The stomach transplanting tumour changes the model of nude mouse was constructed, The mouse was killed in time, and the size of tumor was detected. Virus titer of primary tumor and metastasis and distribution of virus were assayed with immunohistochemistry and In situ hybridization. Resdts： In human cancer of the stomach transplanting turnout changes the model of nude mouse, M1 distributes over primary tumor and metastasis by intravenous infusion, but M1 can inhibit growth of tumor by intravenous infusion. Conclusion： Oncolytic adenovirus can distribute over tumor and metastasis, kill the tumor and plkl.

关 键 词：溶瘤腺病毒 静脉输注 分布 

分 类 号：R373[医药卫生—病原生物学]